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Volume 48, Number 2 Marston et al 405and fewer post-procedure symptoms. The MRV may be use-
ful to evaluate options for patients with combined deep and
superficial disease. Those with a low MRV can be counseled
that EVA is likely to result in improvement or correction of
their symptoms, while those with an unfavorable MRV can
be counseled prior to intervention that they may have
persistent symptoms after ablation allowing them to con-
sider other therapeutic options.
Further study of deep venous tracings in a larger group
of patients is required to confirm the information presented
here. It must be acknowledged that the number of patients
with popliteal or femoral reflux and great saphenous reflux
is relatively limited (n  28) and analysis with a larger
sample size may yield stronger associations. Longer clinical
follow-up would also be useful to determine the durability
of the results after EVA in this patient population. We also
have not yet evaluated the effect of venous outflow obstruc-
tion or incompetent perforators on reflux velocities in the
femoral and popliteal veins. It is possible that correction of
outflow obstruction or perforator incompetence in patients
with distal deep reflux may result in decreased MRV as a
source of symptomatic improvement.
CONCLUSIONS
EVA of the saphenous veins can be performed in pa-
tients with concomitant deep venous insufficiency with
hemodynamic and clinical improvement in most cases.
Patients with femoral or popliteal MRV lower than 10
cm/sec usually experience marked improvement in VFI
and VCSS. Patients with femoral or popliteal reflux veloc-
ities greater than 10 cm/sec in the absence of SSV reflux
have a high incidence of persistent symptoms after EVA.
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Dr. Cynthia Shortell (Durham, NC). I would like to start by
commending Dr. Marston and his colleagues on an extraordinarilyhighly relevant topic to those of interested in venous disease.
Specifically, the authors address the relevance of deep reflux in the
setting of the treatment of superficial reflux. In the 1990s, Dr. John
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August 2008406 Marston et alBergan was one of the first people to identify the fact that some
deep reflux can be corrected by treating superficial reflux. While a
large percent is corrected, there are a significant number of patients
with deep reflux in whom superficial ablation does not correct their
deep reflux. In this paper, Dr. Marston and his colleagues finished
that thought very nicely by identifying the means by which patients
who will improve and those that will not can be differentiated. I do
have a few questions for the authors. First of all, duplex evaluation
does not provide optimal evaluation of iliac vein involvement; and
specifically one is concerned about iliac vein obstruction, and you
did mention a significant number of your patients had a secondary
etiology. Albeit infrequently, this can play a significant role in
looking at infrainguinal reflux and its presence changes the man-
agement of this problem markedly. How do you decide in your
practice whether or not to look for iliac vein lesions such as stenosis
and occlusion and how often is this necessary in your opinion?
Next, in the manuscript I was surprised to see that you didn’t
specifically discuss perforator status on your patients. Do you
routinely look for them, and what role do you think perforators
play in the improvement of symptoms and the change in VFI after
ablation? Specifically, do you think that the treatment of perfora-
tors ever changes a high MRV to a low MRV? I was wondering if
that might be a way to change the prognosis for some of those high
MRV patients. I was interested in the fact that you treat all patients
with varicose veins at the time of your EVA; we actually do a staged
treatment. I was wondering if that reflected the fact that you were
in the camp that believes all patients with varicose veins should
have them removed if they are large because they serve as a later
reservoir for reflux and they contribute to recurrence, or whether
this was more of a convenience of practice protocol. I also wanted
to know how hard the measurement of MRV was for a non-
academic lab as most venous labs are. Is it something that could
readily be applied in general practice so that the non-academic
practitioners could use this as a way of differentiating the appro-
priate from the nonappropriate patients, although one wonders if
that is something that one wants to do. Then, what is your
follow-up protocol? You addressed this a little bit in one of your
slides. Do you use the VCSS and the VFI as sort of a screening tool
to do follow-up duplex? We know that a significant number of
patients will progress or recur after treatment and I was wonderingif you do any routine follow-up duplex of the entire venous system
or only as clinical symptoms warranted. Lastly, I was interested in
knowing what your personal practice is now. Do you offer ETA
with patients with the high MRV? What is your percentage of
indication for deep venous intervention, what sort of intervention
do you use? Have you had any experience with percutaneous
valves?
Dr. William Marston. Thank you Dr. Shortell for those
insightful comments. We do look for iliac vein obstruction and
perforator involvement in all limbs with venous insufficiency. Since
Drs Raju and Neglen have educated us on the frequency of iliac
involvement, we have become more aggressive in looking for and
treating iliac outflow obstruction. Our thoughts on incompetent
perforators have been well documented in the past in a study in
which we found that the majority of incompetent perforators are
no longer incompetent after superficial surgery and varicosity
ablation alone. So our preference is to treat the superficial disease
first, and if the perforators remain, we will treat them later.We have
not yet studied the effect of iliac vein stenting or perforator
ablation on MRV, but I think that is an excellent question. I
personally like to take the varicosities for the more severe patients,
the classes 4-6, and get all those out of there up front. For less
severely affected patients, you can manage the varicosities however
you want based on your practice situation and your patients’
preferences. The MRV is not a difficult measurement to make and
if you just look at the reflux waveforms instead of just looking at a
report, it is easy to tell the difference between a low and highMRV.
It is an easy measurement for the vascular technologists to do and
it doesn’t take much time, less than 20 seconds per tracing.
Basically, my practice now is to always consider ablating the
superficial system in patients with combined deep and superficial
disease as it is possible to get some improvement even in the severe
cases. But I think it is really important to tell the patients ahead of
time that if they have a highMRV it is possible that their symptoms
may not improve entirely. You might need to perform further
intervention to correct their symptoms. In higher risk patients with
combined disease and a high MRV, it may be better to avoid
superficial intervention as there is a lower chance of symptomatic
improvement.
